Document Detail

Urantide Alleviates Monocrotaline Induced Pulmonary Arterial Hypertension in Wistar Rats.
MedLine Citation:
PMID:  21396478     Owner:  NLM     Status:  Publisher    
Pulmonary arterial hypertension (PAH) is a serious disorder with poor prognosis. Urotensin II (UII) has been confirmed to be powerful vasoconstrictor than endothelin-1, which may play an important role in PAH development. The aim of this study is to observe the effects of urantide, a UII receptor antagonist,on monocrotaline (MCT)-induced PAH in rats. 60 male Wistar rats were divided into six groups. For early treatment experiment, rats were divided into normal control group, MCT(4w) model group (MCT+saline×3wks from the 8th day of MCT-injection) and urantide early treatment group (MCT+urantide 10μg/kg/d×3wks, 1 week after MCT injection once). For late treatment experiment, rats were divided as controls, MCT(6w) model group (MCT + saline×2wks, 4 weeks after MCT injection once) and urantide late treatment group (MCT + urantide 10μg/kg/d×2wks, 4 weeks after MCT injection once). At the end of experiments, mean pulmonary arterial pressures (mPAP) and mean blood pressure (MBP) of rats in each group were measured by catheterization. Right ventricular weight ratio was also weighed. Relaxation effects of urantide on intralobar pulmonary arterial rings of normal control and MCT(4w) model rats were investigated. Pulmonary artery remodeling was detected by hematoxylin and eosin (HE) staining and immunohistochemistry analysis. Serum nitric oxide (NO) levels in all six groups were assayed by ELISA kits. Urantide markedly reduced the mPAP levels of MCT induced PAH in both early and late treatment groups. It didn't change the MBP. Urantide dose-dependently relaxed the pulmonary arterial rings of normal control and MCT(4w) model rats. Moreover, N(G)-Nitro-L-arginine Methyl Ester (L-NAME) blocked the dilation response induced by urantide. In addition, urantide inhibited the pulmonary vascular remodeling remarkably. Serum NO level elevated in both early and late treatment rats with urantide infusion. These results suggest that urantide effectively alleviated MCT induced rats PAH may through relaxing pulmonary arteries and inhibiting pulmonary vascular remodeling. NO pathway might be one of the mechanisms in urantide induced pulmonary artery dilation. Thus, it is expected that urantide may be a novel therapy for PAH.
Yifang Mei; Hong Jin; Wei Tian; Hao Wang; Han Wang; Yanping Zhao; Zhiyi Zhang; Fanchao Meng
Related Documents :
12422108 - Prediction of early graft failure with intraoperative completion duplex ultrasound scan.
9262588 - Intraoperative blood flow measurement of the right gastroepiploic artery using pulsed d...
7048368 - An experimental study of the sleeve technique in microarterial anastomoses.
7904148 - Effect of chronic native flow competition on internal thoracic artery grafts.
21332788 - Repair of intraoperative aortic dissection associated with malperfusion syndrome using ...
19546428 - Carotid artery brain aneurysm model: in vivo molecular enzyme-specific mr imaging of ac...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-8
Journal Detail:
Title:  Pulmonary pharmacology & therapeutics     Volume:  -     ISSN:  1522-9629     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9715279     Medline TA:  Pulm Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier Ltd.
The First Affiliated Hospital of Harbin Medical University. 23 You Zheng St. Nan Gang District, Harbin, China. 150001.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Agrobacterium tumefasciens-mediated transformation of the aquatic fungus Blastocladiella emersonii.
Next Document:  Salbutamol delays human eosinophil apoptosis via a cAMP-dependent mechanism.